Access for All: How Late-Stage Neurology and Neuropsychiatry Are Widening the Path to Brain Health

Every year on July 22, the World Federation of Neurology and more than 125 national neurological societies mark World Brain Day, a global observance designed to raise awareness of the burden and promise of brain health. The 2026 theme, Brain Health: Access for All, carries a hard statistical center of gravity: more than 3.4 billion people, or over 40% of the global population, currently live with a neurological condition, making brain disorders the leading cause of disability worldwide.

The access gap is structural. In many regions there is fewer than one neurologist per million people. Cost, wait times, stigma, and language and cultural barriers compound the shortage of specialists. The World Federation of Neurology’s campaign phrase for 2026 puts it plainly: access delayed is potentially access denied. For investors, the observance is not just an awareness moment. It maps directly onto the largest and most under-served market in medicine, and the companies below are working to shorten the delay through different mechanisms, different modalities, and different degrees of success.

Novel Neuropsychiatric Therapeutics: Where Late-Stage Data and Strategic Capital Meet

Depression and anxiety remain the largest categories of untreated brain disease worldwide. Major depressive disorder alone affects an estimated 280 million people globally, and most receive no adequate care. Two companies in this brief are approaching that gap with genuinely novel mechanisms, and in one case a landmark strategic transaction has already priced the thesis.

• Definium Therapeutics (DFTX): Late-stage clinical biopharmaceutical company (rebranded from MindMed in January 2026) developing next-generation therapeutics for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, a lysergide (LSD)-based orally disintegrating tablet, holds FDA Breakthrough Therapy Designation for generalized anxiety disorder. On June 22, 2026, Definium reported positive Phase 3 Emerge topline results in major depressive disorder, with a single 100 µg dose meeting the primary endpoint and demonstrating an 8.1-point placebo-adjusted MADRS improvement at Week 6 (p<0.0001). Two additional Phase 3 GAD readouts and Phase 2a DT402 data in autism spectrum disorder are expected later in 2026. Alongside the topline, Definium priced a $700 million upsized public offering, materially extending a stated runway that already reached into 2028 on the $373.4 million in cash, cash equivalents, and investments Definium reported at March 31. In July, the company launched Wired for Worry, a healthcare-provider initiative advancing understanding of GAD, alongside publication of a healthcare claims study in CNS Spectrums documenting high rates of treatment switching, discontinuation, and prolonged gaps in care among GAD patients.
• AtaiBeckley (ATAI): Clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for treatment-resistant depression and other mental health conditions. On July 16, 2026, Eli Lilly announced a definitive agreement to acquire AtaiBeckley for $6.75 per share in cash upfront, representing an aggregate equity value of approximately $2.8 billion, plus up to $2.50 per share via a contingent value right tied to development and regulatory milestones for BPL-003 and VLS-01 (up to an additional ~$1.0 billion), for a total transaction value of up to approximately $3.8 billion and a 40% premium to AtaiBeckley’s 30-day VWAP through July 15. Lead asset BPL-003, an intranasal mebufotenin benzoate (synthetic 5-MeO-DMT) nasal spray for treatment-resistant depression, holds FDA Breakthrough Therapy Designation and initiated two pivotal Phase 3 trials in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA. On July 6, AtaiBeckley dosed the last patient in Elumina, its Phase 2b trial of VLS-01 (a DMT buccal film) in TRD, with topline data expected in Q4 2026. AtaiBeckley ended Q1 2026 with $209.9 million in cash, cash equivalents, and short-term securities, with a stated runway into 2029 through the anticipated BPL-003 Phase 3 topline readouts. The Lilly transaction is expected to close in Q3 2026, subject to stockholder and regulatory approvals.

Digital Mental Health Access: When Care Delivery Becomes the Access Story

Access to brain health is not only a question of drug development. Reaching patients who never make it into a specialist’s office is the other half of the equation, and one company in this brief has built a platform designed for exactly that.

• Talkspace (TALK): Leading virtual behavioral healthcare provider with a network of approximately 6,000 licensed professionals serving all 50 states, Washington DC, and Puerto Rico, generating $229 million in 2025 revenue and delivering roughly 1.6 million therapy and psychiatry sessions. On March 9, 2026, Universal Health Services entered a definitive agreement to acquire Talkspace for $5.25 per share in cash (approximately $835 million enterprise value). Talkspace stockholders approved the merger on May 29, 2026, with approximately 73.48% of outstanding shares voting in favor, and the transaction is expected to close in Q3 2026 subject to state regulatory approvals. Talkspace ended Q1 2026 with $84.2 million in cash, cash equivalents, and short-term marketable securities and no debt. The company has also developed Tee, its purpose-built mental health large language model, trained on one of the world’s largest mental health datasets. Together, the hospital system, virtual care platform, and purpose-built AI agent offer a working demonstration of what mental health access at population scale can look like as one continuum.

Rare Neurology and Brain Cancer: The Categories Where Access Is Hardest

Brain cancer has historically been among the least accessible corners of oncology, both because glioblastoma is so difficult to treat and because most patients enroll in trials only after standard-of-care options have run out. Rare neurodegenerative diseases are harder still, with late-stage programs advancing against real clinical, regulatory, and financial headwinds.

• Candel Therapeutics (CADL): Clinical-stage biopharmaceutical company developing multimodal viral immunotherapies across solid tumor indications. Its brain cancer program, linoserpaturev (CAN-3110), is a first-in-class replication-competent oncolytic herpes simplex virus-1 immunotherapy being studied in recurrent high-grade glioma. Positive Phase 1b interim data published in Science Translational Medicine reported improved median overall survival compared to historical controls in a therapy-resistant patient population, and a companion paper in Nature documented tolerability and immune activation across the program. Linoserpaturev holds FDA Fast Track Designation and Orphan Drug Designation. Per the Q1 2026 corporate update, the FDA cleared the company’s IND to advance the ongoing program in Q1 2026; mature median OS data from the Phase 1b Arm C expansion are expected in Q4 2026 and will inform the design of a randomized Phase 2 trial in recurrent glioblastoma. In April 2026, Candel entered a commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec, and in late June 2026, Candel appointed Mark Sims as Chief Commercial Officer (effective July 6), signaling preparation for its year-end 2026 aglatimagene BLA submission in localized prostate cancer. Candel reported $194.8 million in cash and cash equivalents at March 31, 2026, with a stated runway into Q1 2028 that supports anticipated commercial launch of aglatimagene in 2027.
• NeuroSense Therapeutics (NRSN): Late-stage clinical biotechnology company developing disease-modifying treatments for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. Its lead candidate, PrimeC, is an extended-release oral fixed-dose combination of ciprofloxacin and celecoxib designed to target multiple pathological mechanisms of ALS simultaneously. On July 22, 2026, following a constructive Pre-NDS meeting with Health Canada, NeuroSense announced its intention to file a New Drug Submission for PrimeC in ALS. The planned submission is supported by the Phase 2b PARADIGM study, which met its primary efficacy endpoint on June 29, 2026, demonstrating a statistically significant reduction in neuron-derived TDP-43, the pathological hallmark present in over 97% of ALS cases, versus placebo at Day 180 (p=0.0421), with the effect persisting and deepening through 18 months. Extended follow-up from PARADIGM previously published in JAMA Neurology reported a 65% reduction in risk of death and a greater than 14-month median survival benefit (HR 0.35, p=0.0037). The FDA-cleared pivotal Phase 3 PARAGON trial is planned to enroll approximately 300 participants primarily in the United States. NeuroSense faces meaningful funding pressure, reporting $0.2 million in cash at year-end 2025 and completing a $600,000 insider-led PIPE financing in April 2026, but the clinical package advancing toward Health Canada is one of the freshest late-stage ALS programs in the field.

Widening the Path

Brain Health: Access for All is not a slogan. It is a framing that recognizes both what modern neurology and neuropsychiatry can now do and what remains out of reach for most of the patients who need it. The companies discussed here operate on the same understanding. Definium Therapeutics (DFTX) delivered the largest positive Phase 3 psychiatry readout of the year and followed it with a substantial capital raise designed to fund commercial preparation. AtaiBeckley (ATAI) priced its late-stage psychedelic pipeline into a definitive Lilly acquisition valued at up to $3.8 billion just days before this year’s observance. Talkspace (TALK) is transitioning under Universal Health Services into what may become the most integrated virtual behavioral healthcare platform in the country. Candel Therapeutics (CADL) is advancing one of the few first-in-class oncolytic virotherapies for recurrent glioblastoma, the most difficult brain cancer in adults. And NeuroSense Therapeutics (NRSN) is advancing PrimeC toward a Health Canada New Drug Submission for ALS on the strength of a Phase 2b program that hit its primary TDP-43 endpoint and produced a 14-month median survival benefit, even as the company navigates real funding pressure.

Access delayed, in the language of the World Federation of Neurology, is potentially access denied. In 2026, the delay is starting to shrink for the categories where the science can now support it, through validated psychiatric therapeutics, virtual care at population scale, precision oncolytic virotherapy, and biomarker-driven programs in ALS. It is still very much present for the millions of patients who cannot yet access what does exist, and for the categories where the underlying biology remains unsolved. Widening the path is not a single event; it is a portfolio of clinical, commercial, and strategic decisions that, taken together, determine who gets brain care and when.

This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. PRISM MarketView is not a registered investment advisor. Companies mentioned are constituents of PRISM indexes; inclusion in an index does not imply endorsement. The clinical-stage and commercial-stage companies discussed carry significant regulatory, clinical, and financial risk, including the possibility of delay, non-approval, or commercial failure. Information is sourced from public filings and reports believed to be reliable but is not guaranteed to be accurate or complete. Readers should conduct their own research and consult a qualified financial advisor before making investment decisions. Past performance is not indicative of future results.